(Clotrimazole + diclofenac sodium) is under clinical development by Profem and currently in Phase III for Vulvovaginal Candidiasis. According to GlobalData, Phase III drugs for Vulvovaginal Candidiasis have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Clotrimazole + diclofenac sodium)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Clotrimazole + diclofenac sodium) overview
Clotrimazole in combination with diclofenac is under development for the treatment of recurrent vulvovaginal candidiasis and dermatological disorders. The drug candidate is administered through vaginal route as a topical formulation. Clotrimazole is an imidazole derivative which acts by targeting the fungal cell membrane. Diclofenac is a nonsteroidal benzeneacetic acid derivative and acts by targeting cyclooxygenase-1 (COX-1) and cyclooxygenase -2 (COX-2).
For a complete picture of (Clotrimazole + diclofenac sodium)’s drug-specific PTSR and LoA scores, buy the report here.